Option Care Health, Inc. (OPCH) · Nov 4, 2026 · Earnings
Beat — Adjusted EPS $0.49 vs ~$0.49 consensus; revenue $1.494B vs ~$1.48B
Option Care Health earnings modestly beat revenue and adjusted EPS expectations, but the pending acquisition removes full-year guidance and the earnings call.
Option Care Health is operating the nation’s largest independent home and alternate-site infusion platform, while its pending acquisition has shifted the company’s story from standalone guidance and public-market execution toward completing the transaction. The merger-related guidance withdrawal was already disclosed before this filing, so the genuinely new information is the quarter’s operating performance. 〔0〕
The quarter landed modestly ahead of published expectations. Revenue reached $1.494 billion versus roughly $1.48 billion expected, while adjusted diluted EPS was $0.49 versus approximately $0.49 consensus. That is a narrow earnings beat, not a major change in the operating trajectory.
| Q3 2026 | Q3 2025 | Consensus | |
|---|---|---|---|
| Net revenue (Income Statement) | $1,493.5M (+4.1%) | $1,435.0M | $1,480M |
| Adjusted EBITDA (Adjusted EBITDA reconciliation) | $124.6M (+4.3%) | $119.5M | |
| Adjusted diluted EPS (Adjusted net income reconciliation) | $0.49 (+8.9%) | $0.45 | $0.49 |
| Net cash from operating activities (Cash Flow statement) | $286.2M (+28.6%) | $222.6M |
Underlying execution was healthy but not transformative. Revenue, adjusted EBITDA and adjusted EPS all improved year over year, and operating cash flow was materially stronger. Still, the gains are consistent with a business progressing on its existing path rather than evidence that the acquisition has unlocked a new growth phase.
The filing removes the full-year benchmark rather than changes the outlook. Because management withdrew its previously disclosed 2026 guidance, investors lose the clearest way to judge fourth-quarter execution against the prior plan. That action was a known consequence of the pending deal, not a fresh operational warning; the transaction—not the quarter itself—remains the dominant strategic development. 〔1〕
Bottom line: Option Care delivered a narrow quarterly beat with better cash generation, but the result only modestly improves the standalone business story. The pending acquisition and withdrawn guidance remain more consequential than the quarter’s incremental upside.
Shareholder vote and merger closing, first half 2027
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!